Novel selective TYK2 inhibitor approved for moderate-to-severe plaque psoriasis. Unique allosteric mechanism targeting regulatory domain offers improved safety vs traditional JAK inhibitors with better selectivity for TYK2.
Selective allosteric inhibition of TYK2 pseudokinase domain (JH2 regulatory region) rather than ATP-competitive binding. Blocks IL-12, IL-23, and Type 1 interferon signaling pathways central to psoriasis pathogenesis. Higher selectivity vs other JAK inhibitors reduces off-target effects.
Selective allosteric inhibition of TYK2 pseudokinase domain (JH2 regulatory region) rather than ATP-competitive binding. Blocks IL-12, IL-23, and Type 1 interferon signaling pathways central to psoriasis pathogenesis. Higher selectivity vs other JAK inhibitors reduces off-target effects.
© 2025[current_year] The Doctors Platform. All Right Reserved.
© 2025 The Doctors Platform. All Right Reserved.
